"We believed that with the clinical trial, Katie had the best chance of recovery. Without these trials, amazing new treatments may never be found."
A study looking at the blood and urine of children being treated for cancer (NUMeRICC)
This study is looking at chemicals and proteins called biomarkers in the blood and urine of children being treated with the chemotherapy drugs cisplatin, ifosfamide or a high dose of methotrexate.
This trial is for children and young people up to and including the age of 18. We use the term 'you', but of course if you are a parent, we are referring to your child.
Doctors often use cisplatin, ifosfamide or methotrexate chemotherapy to treat some types of children’s cancer. Doctors know these drugs can cause kidney damage in some people. In this study they want to look at a particular
The aims of this study are to
- Find out if biomarkers in blood and urine can help to predict who will have kidney damage
- See if some people are more likely to have kidney damage than others, and if there are genetic reasons for this
You will not have any direct benefit from taking part in this study, and it is unlikely to change your treatment plan in any way. But the results of the study will be used to help people with cancer in the future.
Who can enter
This trial will recruit 60 children and young people from Alder Hey Children’s Hospital.
Everybody taking part will give blood and urine samples while they have treatment and 6 and 12 months after they finish treatment.
There are no extra hospital visits with this study. You give your blood and urine samples during routine appointments at the hospital.
The researchers may ask you to collect urine samples while you are at home. They will discuss this with you.
You should not have any side effects from taking part in this study.
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Munir Pirmohamed
Alder Hey Children’s Hospital NHS Foundation Trust
NIHR Clinical Research Network: Cancer
University of Liverpool